Moderna announced on January 25 plans for testing two different booster vaccines aimed at the SARS-CoV-2 variant B.1.351 that emerged in South Africa and has now spread to numerous countries. Moderna COVID-19 Vaccine produced neutralizing titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and Republic of South […]
Moderna published (https://medcitynews.com/2020/09/moderna-publishes-phase-iii-covid-19-vaccine-study-protocol-as-trial-enrolls-more-than-80-of-participants/?rf=1) that the Phase III Covid-19 vaccine study protocol enrolled 25,296 of its planned 30,000 participants which is more than 80% of participants. Of all enrolled subjects, 10,025 have received the full vaccine. This mRNA-1273 Moderna’s vaccine consists of two shots – one delivered on day 1, and a booster shot that participants […]
Pfizer, a pharmaceutical company, in partnership with BioNTech has reported that its lead vaccine candidates has shown promising results in protecting monkeys against coronavirus infections. Pfizer ‘s experimental vaccine is different from other vaccine candidates. This is in an mRNA format, which should allow for a better migration of the viral gene into the cell […]
A transient neutralizing Ab (nAb) response is a feature shared by both COVID19 infection and the coronaviruses that cause common colds (https://www.medrxiv.org/content/10.1101/2020.07.09.20148429v1) Antibody (Ab) responses to SARS-CoV-2 can be detected in most infected individuals 10-15 days following the onset of COVID-19 symptoms. Seroconversion occurred in >95% of cases and neutralizing antibody (nAb) responses. All subjects, […]
Preliminary data suggest that survivors of SARS-CoV-2 infection may be susceptible to reinfection within weeks or months. One study in ~1,500 COVID patients show that 10 percent % of these patients had undetectable antibody levels within weeks of first symptoms or lost their antibodies two to three months after recovering from the infection. Early works […]